• Je něco špatně v tomto záznamu ?

Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis

M. McComb, M. Krikheli, T. Uher, RW. Browne, B. Srpova, J. Oechtering, AM. Maceski, M. Tyblova, D. Jakimovski, DP. Ramasamy, N. Bergsland, J. Krasensky, L. Noskova, L. Fialova, B. Weinstock-Guttman, EK. Havrdova, M. Vaneckova, R. Zivadinov, D....

. 2020 ; 14 (5) : 675-684.e2. [pub] 20200709

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026779

BACKGROUND: The role of cholesterol homeostasis in neuroaxonal injury in multiple sclerosis is not known. OBJECTIVE: The objective of the study is to investigate the associations of cerebrospinal fluid (CSF) and serum neurofilament light chain levels (CSF-NfL and sNfL, respectively), which are biomarkers of neuroaxonal injury, with cholesterol biomarkers at the clinical onset of multiple sclerosis. METHODS: sNfL, serum cholesterol profile (total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), serum apolipoprotein (Apo) levels (ApoA-I, ApoA-II, ApoB, and ApoE), and albumin quotient were obtained for 133 patients (63% female, age: 29.9 ± 8.0 years) during the first demyelinating event. CSF-NfL was available for 103 (77%) patients. RESULTS: CSF-NfL and sNfL were negatively associated with serum ApoA-II (P = .005, P < .001) and positively associated with albumin quotient (P < .001, P < .0001). In addition, higher CSF-NfL was associated with lower serum ApoA-I (P = .009) levels and higher sNfL was associated with lower high-density lipoprotein cholesterol (P = .010). In stepwise regression, age (P = .045), serum ApoA-II (P = .022), and albumin quotient (P < .001) were associated with CSF-NfL; albumin quotient (P = .002) and ApoA-II (P = .001) were associated with sNfL. Path analysis identified parallel pathways from ApoA-II (P = .009) and albumin quotient (P < .001) to the sNfL outcome that were mediated by CSF-NfL (P < .001). The associations of CSF-NfL with ApoA-I (P = .014) and ApoA-II (P = .015) and sNfL with ApoA-II (P < .001) remained significant after adjusting for number of contrast-enhancing lesions and T2 lesion volume. CONCLUSION: Lower serum ApoA-II and ApoA-I levels are associated with greater neuroaxonal injury as measured by CSF-NfL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026779
003      
CZ-PrNML
005      
20240903113346.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacl.2020.07.001 $2 doi
035    __
$a (PubMed)32758395
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a McComb, Mason $u Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA
245    10
$a Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis / $c M. McComb, M. Krikheli, T. Uher, RW. Browne, B. Srpova, J. Oechtering, AM. Maceski, M. Tyblova, D. Jakimovski, DP. Ramasamy, N. Bergsland, J. Krasensky, L. Noskova, L. Fialova, B. Weinstock-Guttman, EK. Havrdova, M. Vaneckova, R. Zivadinov, D. Horakova, J. Kuhle, M. Ramanathan
520    9_
$a BACKGROUND: The role of cholesterol homeostasis in neuroaxonal injury in multiple sclerosis is not known. OBJECTIVE: The objective of the study is to investigate the associations of cerebrospinal fluid (CSF) and serum neurofilament light chain levels (CSF-NfL and sNfL, respectively), which are biomarkers of neuroaxonal injury, with cholesterol biomarkers at the clinical onset of multiple sclerosis. METHODS: sNfL, serum cholesterol profile (total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), serum apolipoprotein (Apo) levels (ApoA-I, ApoA-II, ApoB, and ApoE), and albumin quotient were obtained for 133 patients (63% female, age: 29.9 ± 8.0 years) during the first demyelinating event. CSF-NfL was available for 103 (77%) patients. RESULTS: CSF-NfL and sNfL were negatively associated with serum ApoA-II (P = .005, P < .001) and positively associated with albumin quotient (P < .001, P < .0001). In addition, higher CSF-NfL was associated with lower serum ApoA-I (P = .009) levels and higher sNfL was associated with lower high-density lipoprotein cholesterol (P = .010). In stepwise regression, age (P = .045), serum ApoA-II (P = .022), and albumin quotient (P < .001) were associated with CSF-NfL; albumin quotient (P = .002) and ApoA-II (P = .001) were associated with sNfL. Path analysis identified parallel pathways from ApoA-II (P = .009) and albumin quotient (P < .001) to the sNfL outcome that were mediated by CSF-NfL (P < .001). The associations of CSF-NfL with ApoA-I (P = .014) and ApoA-II (P = .015) and sNfL with ApoA-II (P < .001) remained significant after adjusting for number of contrast-enhancing lesions and T2 lesion volume. CONCLUSION: Lower serum ApoA-II and ApoA-I levels are associated with greater neuroaxonal injury as measured by CSF-NfL.
650    _2
$a dospělí $7 D000328
650    _2
$a apolipoprotein A-I $x krev $7 D016632
650    _2
$a apolipoprotein A-II $x krev $7 D016633
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x krev $x mozkomíšní mok $x patologie $7 D009103
650    _2
$a neurofilamentové proteiny $x mozkomíšní mok $7 D016900
650    _2
$a neuroprotektivní látky $x krev $x mozkomíšní mok $7 D018696
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krikheli, Maggie $u Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA
700    1_
$a Uher, Tomas $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Browne, Richard W $u Department of Biotechnical and Clinical Laboratory Sciences, State University of New York, Buffalo, NY, USA
700    1_
$a Srpová, Barbora $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic $7 xx0321726
700    1_
$a Oechtering, Johanna $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Maceski, Aleksandra Maleska $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Tyblova, Michaela $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Jakimovski, Dejan $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA
700    1_
$a Ramasamy, Deepa P $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA
700    1_
$a Bergsland, Niels $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA; IRCCS, Fondazione Don Carlo Gnocchi, Milan, Italy
700    1_
$a Krasensky, Jan $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
700    1_
$a Noskova, Libuse $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Fialova, Lenka $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Weinstock-Guttman, Bianca $u Department of Neurology, State University of New York, Buffalo, NY, USA
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Vaneckova, Manuela $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
700    1_
$a Zivadinov, Robert $u Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA; Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, Buffalo, NY, USA
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, First Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Kuhle, Jens $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Ramanathan, Murali $u Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA; Department of Neurology, State University of New York, Buffalo, NY, USA. Electronic address: Murali@Buffalo.Edu
773    0_
$w MED00166943 $t Journal of clinical lipidology $x 1933-2874 $g Roč. 14, č. 5 (2020), s. 675-684.e2
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32758395 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240903113343 $b ABA008
999    __
$a ok $b bmc $g 1715507 $s 1147286
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 14 $c 5 $d 675-684.e2 $e 20200709 $i 1933-2874 $m Journal of clinical lipidology $n J. clin. lipidol. $x MED00166943
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace